A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
Indications Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PANTHERA
Sponsors Celltrion; Merck Sharp & Dohme

01 Sep 2023 Results of an analysis monitoring outcomes of systemic chemotherapy using serially collected ctDNA of 15 HER2-positive metastatic GC patients treated with anti-PD-1 inhibitor in combination with standard systemic treatment published in the Yonsei Medical Journal
17 Jan 2021 Results of updated clinical data and molecular profiling results presented at the 2021 Gastrointestinal Cancers Symposium
17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com